This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Clopidogrel and CYP2C19 gene

Authoring team

CYP2C19 gene and clopidogrel

  • large variability in anti-platelet effects in clopidogrel-treated patients after PCI
    • this is partly due to genetic variations in the CYP2C19 gene (1)

  • carriers of a CYP2C19*2 or *3 loss-of-function (LoF) allele are at higher risk for high platelet reactivity when treated with clopidogrel

  • patients who carry a CYP2C19*17 gain-of-function (GoF) allele might have better efficacy of clopidogrel and a possibly higher risk for bleeding with clopidogrel compared to non-carriers of the variant (2)

  • prespecified subanalysis of the POPular Genetics trial assessed the effect of the CYP2C19*17 GoF allele in clopidogrel-treated patients and safety and efficacy of clopidogrel in patients without a CYP2C19*2 or *3 LoF allele compared to patients who received treatment of ticagrelor or prasugrel irrespective of their genotype
    • showed that treatment with clopidogrel was associated with less bleeding without an increase in thrombotic outcomes after PCI in STEMI patients without a CYP2C19*2 or *3 LoF allele, compared to patients with standard ticagrelor or prasugrel treatment. No significant differences in thrombotic or bleeding outcomes were found with use of clopidogrel in carriers of a CYP2C19*17 allele compared to patients with wild-type alleles

Reference:

  1. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-762. doi:10.1001/jama.2010.181
  2. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel treated patients. J Thromb Haemost. 2012;10:199-206. doi:10.1111/j.1538-7836.2011.04570.x
  3. Claassens DMF, Bergmeijer TO, Vos GJA, et al. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis. Circ Cardiovasc Interv. 2021 doi:0.1161/CIRCINTERVENTIONS.120.009434

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.